Skip to main content
Top
Published in: AIDS and Behavior 8/2023

17-01-2023 | Care | Original Paper

Understanding Barriers and Facilitators of Pre-exposure Prophylaxis (PrEP) Among Transgender and Gender Diverse Adults in an Integrated Health Care System

Authors: Katia Bruxvoort, Cecilia Portugal, Mercedes Munis, Katherine Pak, Rulin Hechter

Published in: AIDS and Behavior | Issue 8/2023

Login to get access

Abstract

Transgender and gender diverse individuals face health disparities such as higher HIV prevalence, but limited studies have found low PrEP uptake among these populations. To understand both patient and provider perspectives regarding PrEP care for transgender and gender diverse individuals, we conducted a mixed-methods study at Kaiser Permanente Southern California from September 2020 to October 2021. Transgender and gender diverse adults (N = 396) participated in a web-based survey, and qualitative interviews were subsequently conducted with a subset of survey respondents (N = 32) and healthcare providers (N = 8). Among survey respondents, > 75% were familiar with PrEP, and > 40% reported at least one HIV risk factor, but < 5% had taken PrEP. Interview themes included increasing providers’ inclusivity in primary care for transgender and gender diverse patients, and reducing logistical barriers and costs associated with PrEP-related visits. To improve PrEP uptake among transgender and gender diverse individuals, barriers across patient, provider, and health system levels must be addressed.
Appendix
Available only for authorised users
Literature
1.
go back to reference HIV.gov. Data & trends U.S. statistics, fast facts. HIV GOV. June 02, 2021. HIV.gov. Data & trends U.S. statistics, fast facts. HIV GOV. June 02, 2021.
2.
go back to reference Centers for Disease Control and Prevention. HIV surveillance report 2018 (updated). 2020. Centers for Disease Control and Prevention. HIV surveillance report 2018 (updated). 2020.
3.
go back to reference Poteat T, Malik M, Wirtz AL, Cooney EE, Reisner S. Understanding HIV risk and vulnerability among cisgender men with transgender partners. Lancet HIV. 2020;7(3):e201–8.CrossRefPubMed Poteat T, Malik M, Wirtz AL, Cooney EE, Reisner S. Understanding HIV risk and vulnerability among cisgender men with transgender partners. Lancet HIV. 2020;7(3):e201–8.CrossRefPubMed
4.
go back to reference Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health. 2019;109(1):e1–8.CrossRefPubMedPubMedCentral Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health. 2019;109(1):e1–8.CrossRefPubMedPubMedCentral
5.
go back to reference Gamarel KE, Sevelius JM, Reisner SL, Richardson RL, Darbes LA, Nemoto T, et al. Relationship stigma and HIV risk behavior among cisgender men partnered with transgender women: the moderating role of sexual identity. Arch Sex Behav. 2020;49(1):175–84.CrossRefPubMed Gamarel KE, Sevelius JM, Reisner SL, Richardson RL, Darbes LA, Nemoto T, et al. Relationship stigma and HIV risk behavior among cisgender men partnered with transgender women: the moderating role of sexual identity. Arch Sex Behav. 2020;49(1):175–84.CrossRefPubMed
6.
go back to reference Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, et al. Barriers and facilitators to oral PrEP use among transgender women in New York City. AIDS Behav. 2018;22(11):3627–36.CrossRefPubMedPubMedCentral Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, et al. Barriers and facilitators to oral PrEP use among transgender women in New York City. AIDS Behav. 2018;22(11):3627–36.CrossRefPubMedPubMedCentral
7.
go back to reference Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22.CrossRefPubMed Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22.CrossRefPubMed
8.
go back to reference Cairns G. Sex, PrEP and HIV in trans and non-binary people. A research briefing. nam aidsmap 2021 (March 2021). Cairns G. Sex, PrEP and HIV in trans and non-binary people. A research briefing. nam aidsmap 2021 (March 2021).
9.
go back to reference Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. 2021. Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. 2021.
10.
go back to reference Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–9.CrossRefPubMedPubMedCentral Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–9.CrossRefPubMedPubMedCentral
11.
go back to reference Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239–54.CrossRefPubMedPubMedCentral Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239–54.CrossRefPubMedPubMedCentral
12.
go back to reference Hojilla JC, Hurley LB, Marcus JL, Satre DD, Silverberg MJ, Zaritsky EF, et al. HIV pre-exposure prophylaxis continuum of care among transgender individuals in an integrated health care system. J Acquir Immune Defic Syndr. 2022;89(3): e30.CrossRefPubMedPubMedCentral Hojilla JC, Hurley LB, Marcus JL, Satre DD, Silverberg MJ, Zaritsky EF, et al. HIV pre-exposure prophylaxis continuum of care among transgender individuals in an integrated health care system. J Acquir Immune Defic Syndr. 2022;89(3): e30.CrossRefPubMedPubMedCentral
13.
go back to reference Wilson EC, Hernandez CJ, Scheer S, Trujillo D, Arayasirikul S, Sicro S, et al. Improved PrEP awareness and use among trans women in San Francisco, California. AIDS Behav. 2022;26(2):596–603.CrossRefPubMed Wilson EC, Hernandez CJ, Scheer S, Trujillo D, Arayasirikul S, Sicro S, et al. Improved PrEP awareness and use among trans women in San Francisco, California. AIDS Behav. 2022;26(2):596–603.CrossRefPubMed
14.
go back to reference Wilson EC, Turner CM, Arayasirikul S, Lightfoot M, Scheer S, Raymond HF, et al. Disparities in the PrEP continuum for trans women compared to MSM in San Francisco, California: results from population-based cross-sectional behavioural surveillance studies. J Int AIDS Soc. 2020;23(Suppl 3): e25539.PubMedPubMedCentral Wilson EC, Turner CM, Arayasirikul S, Lightfoot M, Scheer S, Raymond HF, et al. Disparities in the PrEP continuum for trans women compared to MSM in San Francisco, California: results from population-based cross-sectional behavioural surveillance studies. J Int AIDS Soc. 2020;23(Suppl 3): e25539.PubMedPubMedCentral
15.
go back to reference Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, et al. Knowledge about oral PrEP among transgender women in New York City. AIDS Behav. 2019;23(10):2779–83.CrossRefPubMedPubMedCentral Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, et al. Knowledge about oral PrEP among transgender women in New York City. AIDS Behav. 2019;23(10):2779–83.CrossRefPubMedPubMedCentral
16.
go back to reference Cahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH. Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017;29(11):1351–8.CrossRefPubMedPubMedCentral Cahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH. Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017;29(11):1351–8.CrossRefPubMedPubMedCentral
17.
go back to reference D’Avanzo PA, Bass SB, Brajuha J, Gutierrez-Mock L, Ventriglia N, Wellington C, et al. Medical mistrust and PrEP perceptions among transgender women: a cluster analysis. Behav Med (Washington, DC). 2019;45(2):143–52.CrossRef D’Avanzo PA, Bass SB, Brajuha J, Gutierrez-Mock L, Ventriglia N, Wellington C, et al. Medical mistrust and PrEP perceptions among transgender women: a cluster analysis. Behav Med (Washington, DC). 2019;45(2):143–52.CrossRef
18.
go back to reference Cahill SR, Keatley J, Wade Taylor S, Sevelius J, Elsesser SA, Geffen SR, et al. “Some of us, we don’t know where we’re going to be tomorrow.” Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco. AIDS Care. 2020;32(5):585–93.CrossRefPubMed Cahill SR, Keatley J, Wade Taylor S, Sevelius J, Elsesser SA, Geffen SR, et al. “Some of us, we don’t know where we’re going to be tomorrow.” Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco. AIDS Care. 2020;32(5):585–93.CrossRefPubMed
20.
go back to reference Watson CW, Pasipanodya E, Savin MJ, Ellorin EE, Corado KC, Flynn RP, et al. Barriers and facilitators to PrEP initiation and adherence among transgender and gender non-binary individuals in Southern California. AIDS Educ Prev. 2020;32(6):472–85.CrossRefPubMed Watson CW, Pasipanodya E, Savin MJ, Ellorin EE, Corado KC, Flynn RP, et al. Barriers and facilitators to PrEP initiation and adherence among transgender and gender non-binary individuals in Southern California. AIDS Educ Prev. 2020;32(6):472–85.CrossRefPubMed
21.
go back to reference Holder CL, Perez-Gilbe HR, Fajardo FJ, Garcia S, Cyrus E. Disparities of HIV risk and PrEP use among transgender women of color in South Florida. J Natl Med Assoc. 2019;111(6):625–32.PubMed Holder CL, Perez-Gilbe HR, Fajardo FJ, Garcia S, Cyrus E. Disparities of HIV risk and PrEP use among transgender women of color in South Florida. J Natl Med Assoc. 2019;111(6):625–32.PubMed
22.
go back to reference Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012;16(3):37–41.CrossRefPubMedPubMedCentral Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012;16(3):37–41.CrossRefPubMedPubMedCentral
23.
go back to reference Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc. 1973;51(1):95–124.CrossRefPubMed Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc. 1973;51(1):95–124.CrossRefPubMed
24.
go back to reference Poteat T, Wirtz A, Malik M, Cooney E, Cannon C, Hardy WD, et al. A gap between willingness and uptake: findings from mixed methods research on HIV prevention among Black and Latina transgender women. J Acquir Immune Defic Syndr. 2019;82(2):131–40.CrossRefPubMedPubMedCentral Poteat T, Wirtz A, Malik M, Cooney E, Cannon C, Hardy WD, et al. A gap between willingness and uptake: findings from mixed methods research on HIV prevention among Black and Latina transgender women. J Acquir Immune Defic Syndr. 2019;82(2):131–40.CrossRefPubMedPubMedCentral
25.
go back to reference Poteat TC, Radix A. HIV antiretroviral treatment and pre-exposure prophylaxis in transgender individuals. Drugs. 2020;80(10):965–72.CrossRefPubMed Poteat TC, Radix A. HIV antiretroviral treatment and pre-exposure prophylaxis in transgender individuals. Drugs. 2020;80(10):965–72.CrossRefPubMed
26.
go back to reference Zarwell M, John SA, Westmoreland D, Mirzayi C, Pantalone DW, Golub S, Nash D, Grov C. PrEP Uptake and discontinuation among a U.S. national sample of transgender men and women. AIDS Behav. 2021;25(4):1063–71.CrossRefPubMed Zarwell M, John SA, Westmoreland D, Mirzayi C, Pantalone DW, Golub S, Nash D, Grov C. PrEP Uptake and discontinuation among a U.S. national sample of transgender men and women. AIDS Behav. 2021;25(4):1063–71.CrossRefPubMed
27.
go back to reference Nieto O, Brooks RA, Landrian A, Cabral A, Fehrenbacher AE. PrEP discontinuation among Latino/a and Black MSM and transgender women: a need for PrEP support services. PLoS ONE. 2020;15(11): e0241340.CrossRefPubMedPubMedCentral Nieto O, Brooks RA, Landrian A, Cabral A, Fehrenbacher AE. PrEP discontinuation among Latino/a and Black MSM and transgender women: a need for PrEP support services. PLoS ONE. 2020;15(11): e0241340.CrossRefPubMedPubMedCentral
29.
go back to reference Siegler AJ, Steehler K, Sales JM, Krakower DS. A review of HIV pre-exposure prophylaxis streamlining strategies. Curr HIV/AIDS Rep. 2020;17(6):643–53.CrossRefPubMedPubMedCentral Siegler AJ, Steehler K, Sales JM, Krakower DS. A review of HIV pre-exposure prophylaxis streamlining strategies. Curr HIV/AIDS Rep. 2020;17(6):643–53.CrossRefPubMedPubMedCentral
30.
go back to reference Bruxvoort KJ, Schumacher CM, Towner W, Jones J, Contreras R, Ling Grant D, et al. Referral linkage to preexposure prophylaxis care and persistence on preexposure prophylaxis in an integrated health care system. J Acquir Immune Defic Syndr. 2021;87(3):918–27.CrossRefPubMed Bruxvoort KJ, Schumacher CM, Towner W, Jones J, Contreras R, Ling Grant D, et al. Referral linkage to preexposure prophylaxis care and persistence on preexposure prophylaxis in an integrated health care system. J Acquir Immune Defic Syndr. 2021;87(3):918–27.CrossRefPubMed
31.
go back to reference Golub SA, Fikslin RA, Goldberg MH, Peña SM, Radix A. Predictors of PrEP uptake among patients with equivalent access. AIDS Behav. 2019;23(7):1917–24.CrossRefPubMedPubMedCentral Golub SA, Fikslin RA, Goldberg MH, Peña SM, Radix A. Predictors of PrEP uptake among patients with equivalent access. AIDS Behav. 2019;23(7):1917–24.CrossRefPubMedPubMedCentral
33.
go back to reference Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256–67.CrossRefPubMedPubMedCentral Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256–67.CrossRefPubMedPubMedCentral
34.
go back to reference Miller SJ, Harrison SE, Sanasi-Bhola K. A scoping review investigating relationships between depression, anxiety, and the PrEP care continuum in the United States. Int J Environ Res Public Health. 2021;18(21):11431.CrossRefPubMedPubMedCentral Miller SJ, Harrison SE, Sanasi-Bhola K. A scoping review investigating relationships between depression, anxiety, and the PrEP care continuum in the United States. Int J Environ Res Public Health. 2021;18(21):11431.CrossRefPubMedPubMedCentral
35.
go back to reference Ogunbajo A, Storholm ED, Ober AJ, Bogart LM, Reback CJ, Flynn R, et al. Multilevel barriers to HIV PrEP uptake and adherence among Black and Hispanic/Latinx transgender women in Southern California. AIDS Behav. 2021;25(7):2301–15.CrossRefPubMedPubMedCentral Ogunbajo A, Storholm ED, Ober AJ, Bogart LM, Reback CJ, Flynn R, et al. Multilevel barriers to HIV PrEP uptake and adherence among Black and Hispanic/Latinx transgender women in Southern California. AIDS Behav. 2021;25(7):2301–15.CrossRefPubMedPubMedCentral
Metadata
Title
Understanding Barriers and Facilitators of Pre-exposure Prophylaxis (PrEP) Among Transgender and Gender Diverse Adults in an Integrated Health Care System
Authors
Katia Bruxvoort
Cecilia Portugal
Mercedes Munis
Katherine Pak
Rulin Hechter
Publication date
17-01-2023
Publisher
Springer US
Published in
AIDS and Behavior / Issue 8/2023
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-023-03983-8

Other articles of this Issue 8/2023

AIDS and Behavior 8/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine